Accenture, Hewlett Packard Enterprise And 2 Other Stocks Insiders Are Selling
Portfolio Pulse from Lisa Levin
Insiders at Moderna, Inc. (MRNA), Hewlett Packard Enterprise Company (HPE), Exact Sciences Corporation (EXAS), and Accenture plc (ACN) have recently sold shares. The reasons for these sales are not clear, but they could be due to preplanned sales or concerns about the companies' prospects. These sales should not be the sole indicator for investment decisions, but they can lend conviction to a selling decision.
July 31, 2023 | 11:59 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Accenture's General Counsel/Corp Secretary sold 7,000 shares at an average price of $320.60. The company recently announced leadership appointments.
Insider selling can sometimes indicate a lack of confidence in the company's future prospects. However, Accenture's recent leadership appointments could potentially offset this negative signal.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Exact Sciences' Director sold 2,000 shares at an average price of $97.42. The company recently announced that its Cologuard test demonstrated 94% sensitivity for colorectal cancer.
Insider selling can sometimes indicate a lack of confidence in the company's future prospects. However, Exact Sciences' recent announcement about its Cologuard test could potentially offset this negative signal.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Hewlett Packard's SVP Controller and CTO sold 21,131 shares at an average price of $17.66. The company recently collaborated with Applied Digital to deliver energy-efficient supercomputers.
Insider selling can sometimes indicate a lack of confidence in the company's future prospects. However, Hewlett Packard's recent collaboration with Applied Digital could potentially offset this negative signal.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Moderna's Director sold 15,000 shares at an average price of $120.42. The company recently initiated a pivotal Phase 3 trial for a new therapy.
Insider selling can sometimes indicate a lack of confidence in the company's future prospects. However, Moderna has recently initiated a pivotal Phase 3 trial, which could potentially offset this negative signal.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100